Annals of Nuclear Medicine最新文献

{"title":"The 1st World Congress of Nuclear Medicine and Biology held in Japan: a historical review with personal reminiscences","authors":"Yasuhito Sasaki","doi":"10.1007/s12149-024-01988-4","DOIUrl":"10.1007/s12149-024-01988-4","url":null,"abstract":"<div><p>The 1st World Congress of Nuclear Medicine and Biology was held from September 30 to October 4 1974 in Japan. This was an epoch-making event in the history of Nuclear Medicine in Japan as well as in the World. The huge success of the meeting contributed a lot to the rapid and remarkable progress of nuclear medicine thereafter. The author served as a secretary of the local organizing committee for the Congress. The author would like to record the event summarizing the publications made by the local organization committee. The author would like to share with nuclear medicine professionals of younger generations the unforgettable experiences which he has kept in memory for the past half a century. The author believes this historical review will help to pave the future way of nuclear medicine by recalling how the World Federation and Congress was started with the great efforts of the excellent minds of predecessors.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 1","pages":"1 - 8"},"PeriodicalIF":2.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors","authors":"Masao Watanabe,&nbsp;Wolfgang P. Fendler,&nbsp;Hong Grafe,&nbsp;Nader Hirmas,&nbsp;Rainer Hamacher,&nbsp;Helena Lanzafame,&nbsp;Kim M. Pabst,&nbsp;Hubertus Hautzel,&nbsp;Clemens Aigner,&nbsp;Stefan Kasper,&nbsp;Bastian von Tresckow,&nbsp;Martin Stuschke,&nbsp;Sherko Kümmel,&nbsp;Celine Lugnier,&nbsp;Boris Hadaschik,&nbsp;Viktor Grünwald,&nbsp;Fadi Zarrad,&nbsp;David Kersting,&nbsp;Jens T. Siveke,&nbsp;Ken Herrmann,&nbsp;Manuel Weber","doi":"10.1007/s12149-024-01993-7","DOIUrl":"10.1007/s12149-024-01993-7","url":null,"abstract":"<div><h3>Objective</h3><p>FAPI-PET/CT exhibits high tumor uptake and low background accumulation, enabling high-sensitivity tumor detection. We compared the diagnostic performance of ⁶⁸ Ga-FAPI-46 PET/CT plus contrast-enhanced CT (CE-CT), ¹⁸F-FDG PET/CT plus CE-CT, and standalone CE-CT in patients with various malignancies.</p><h3>Methods</h3><p>232 patients underwent ⁶⁸ Ga-FAPI-46 PET/CT,¹⁸F-FDG PET/CT, and CE-CT each within 4 weeks. Detection rates were assessed by a blinded reader, with ≥ 2 weeks between scans of the same patient to avoid recall bias. A sub-analysis of diagnostic performance was performed for 490 histopathologically validated lesions. Detection rates were compared using McNemar’s test.</p><h3>Results</h3><p>Lesion-based detection rates in ⁶⁸ Ga-FAPI-46 PET/CT plus CE-CT, ¹⁸F-FDG PET/CT plus CE-CT, and CE-CT alone were 91.2% (1540/1688), 82.5% (1393/1688) and 60.2% (1016/1688). The detection rates were significantly higher for ⁶⁸ Ga-FAPI-46 PET/CT plus CE-CT than for ¹⁸F-FDG PET/CT plus CE-CT (<i>p</i> &lt; 0.02 for primary lesions and p &lt; 0.001 for total, abdominopelvic nodal, liver and other visceral lesions) and CE-CT (<i>p</i> &lt; 0.0001 for total, primary, cervicothoracic nodal, abdominopelvic nodal, liver, other visceral, and bone lesions). In the sub-analysis, sensitivity, specificity, positive and negative predictive value, and accuracy were 61.3%, 96.7%, 81.4%, 91.4% and 90.0% for ⁶⁸ Ga-FAPI-46 PET/CT plus CE-CT, 57.0%, 95.7%, 75.7%, 90.5% and 88.4% for ¹⁸F-FDG PET/CT plus CE-CT, and 51.6%, 97.2%, 81.4%, 89.6% and 88.6% for CECT, respectively.</p><h3>Conclusions</h3><p>⁶⁸ Ga-FAPI-46 PET/CT plus CE-CT demonstrates a higher tumor detection rate than ¹⁸F-FDG PET/CT plus CE-CT and CE-CT in a diverse spectrum of malignancies, especially for primary, abdominopelvic nodal, liver, and other visceral lesions. Further studies on which entities draw particular benefit from ⁶⁸ Ga-FAPI-46 PET/CT are warranted to aid appropriate diagnostic workup.</p><h3>Trial registration</h3><p>A total of <i>N</i> = 232 patients were analyzed. Of these, <i>N</i> = 50 patients were included in a prospective interventional trial (NCT05160051), and <i>N</i> = 175 in a prospective observational trial (NCT04571086) for correlation and clinical follow-up of PET findings; <i>N</i> = 7 patients were analyzed retrospectively.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 3","pages":"255 - 265"},"PeriodicalIF":2.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of liver standardized uptake value in F18-FDG PET/CT scanning: impact of different malignancies, blood glucose level, body weight normalization, and imaging systems","authors":"Mohamed S. Abd-Elkader,&nbsp;Sherif M. Elmaghraby,&nbsp;Mohamed A. Abdel-Mohsen,&nbsp;Magdy M. Khalil","doi":"10.1007/s12149-024-01985-7","DOIUrl":"10.1007/s12149-024-01985-7","url":null,"abstract":"<div><h3>Introduction</h3><p>The aim of this work was to investigate homogeneity and stability of liver SUV in terms of different malignancies considering different body normalization schemes and blood glucose concentrations as well as PET/CT imaging systems.</p><h3>Methods</h3><p>The study included 207 patients with four different types of cancers namely breast, lymphoma, lung, and bone-metastasis. Data acquisition was performed with GE Discovery IQ, Biograph mCT, uMI 550, and Ingenuity TF64 after a single intravenous injection of 194 ± 67.5 MBq of 18F-FDG.</p><h3>Results</h3><p>In body weight normalization, SUVmax and SUVmean in bone-mets as well as SUVmean in lung patients were not statistically different among scanners especially for data corrected for glucose levels (<i>p = </i>0.062, 0.121, and 0.150, respectively). In SUVlbm derived from lung patients, there was no significant differences in Philips in comparison to GE and Siemens (both, <i>p &gt; </i>0.05) for data corrected and not corrected for glucose levels. In SUVbsa, the only non-significant difference revealed among scanners was in the measurements of SUVmean obtained from lung and bone-mets (<i>p = </i>0.107 and 0.114) both corrected for glucose levels. In SUVbmi, SUVmean of lung and bone-mets as well as SUVmax of bone-mets showed a non-significant differences among the four different scanning systems (<i>p = </i>0.303, 0.091, and 0.222, respectively) for data corrected for glucose levels.</p><h3>Conclusion</h3><p>Liver glucose correction needs further investigations in individual tumors but could be potentially affected by whether measurements are made on SUVmean versus SUVmax, body weight normalization, as well as the imaging system. As such, selection of normalization to body weight method should be carefully selected before clinical adoption and clinically adopted and body surface area would provide the highest correlation. As such, normalization of body weight should be carefully made before clinical adoption. SUVmean proves to be useful and stable metric when liver is corrected for blood glucose levels.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"176 - 188"},"PeriodicalIF":2.5,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-024-01985-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Clinical assessment and striatal dopaminergic activity in healthy controls and patients with Parkinson’s disease: a Bayesian approach","authors":"Seunghyeon Shin,&nbsp;Hyun-Yeol Nam,&nbsp;Keunyoung Kim,&nbsp;Jihyun Kim,&nbsp;Myung Jun Lee,&nbsp;Kyoungjune Pak","doi":"10.1007/s12149-024-01989-3","DOIUrl":"10.1007/s12149-024-01989-3","url":null,"abstract":"","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 12","pages":"999 - 999"},"PeriodicalIF":2.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer","authors":"Qaid Ahmed Shagera,&nbsp;Thierry Gil,&nbsp;Elisa Barraco,&nbsp;Petra Boegner,&nbsp;Paulus Kristanto,&nbsp;Ziad El Ali,&nbsp;Spyridon Sideris,&nbsp;Nieves Martinez Chanza,&nbsp;Thierry Roumeguère,&nbsp;Patrick Flamen,&nbsp;Carlos Artigas","doi":"10.1007/s12149-024-01990-w","DOIUrl":"10.1007/s12149-024-01990-w","url":null,"abstract":"<div><h3>Aim</h3><p>Conventional imaging techniques and prostate-specific antigen (PSA) values are not useful to follow-up patients during Radium-223 treatment. The study aimed to evaluate the predictive value of prostate-specific membrane antigen PSMA PET/CT-based response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Radium-223 dichloride treatment.</p><h3>Materials and methods</h3><p>Patients treated with radium-223, having performed two ⁶⁸Ga-PSMA-11 PET/CT scans (baseline 1 month before treatment initiation and follow-up 2 weeks after the third cycle), were retrospectively evaluated. Visual and quantitative PET image analyses were performed, and patients were dichotomized into progressive (PD) and non-PD according to Response Evaluation Criteria in PSMA‑imaging (RECIP1.0) and PSMA-PET Progression criteria (PPP). The primary endpoint was overall survival (OS). Cohen's Kappa (<i>κ</i>) was used to test the agreement between the two criteria. The Cox regression hazard model and Kaplan–Meier method were used for survival analyses.</p><h3>Results</h3><p>Twenty-eight mCRPC patients were evaluated. Sixteen (43%) and 18 (64%) patients had PD according to RECIP1.0 and PPP, respectively; <i>κ</i> = 0.85 (95% CI 0.65–1.00). After a median follow-up of 16 months (interquartile IQR 9–33), 20 (71%) patients died. Patients with PSMA PD showed a higher risk of death than non-PD according to RECIP1.0 (HR = 2.9; 95% CI 1.14–7.46; <i>p</i> = 0.029) and PPP (HR = 2.8; 95% CI 1.04–7.64; <i>p</i> = 0.042). For both criteria, the median OS was shorter for PD than non-PD (37 vs. 12 months, Log-rank; <i>p</i> &lt; 0.05). The <i>C</i>-index for RECIP1.0 and PPP were almost equal (0.66 and 0.63; respectively).</p><h3>Conclusion</h3><p>This study demonstrated that PSMA-PET/CT imaging is valuable for monitoring radium-223 treatment. Both PSMA PET/CT response criteria (RECIP1.0 and PPP) perform similarly predicting OS at follow-up after three cycles of radium-223. These findings urge further validation in prospective trials.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"208 - 216"},"PeriodicalIF":2.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Monte Carlo study comparing dead-time losses of a gamma camera between tungsten functional paper and lead sheet for dosimetry in targeted radionuclide therapy with Lu-177","authors":"Kohei Nakanishi,&nbsp;Naotoshi Fujita,&nbsp;Haruna Iwanaga,&nbsp;Yuki Asano,&nbsp;Shinji Abe,&nbsp;Ryuichi Nishii,&nbsp;Katsuhiko Kato","doi":"10.1007/s12149-024-01987-5","DOIUrl":"10.1007/s12149-024-01987-5","url":null,"abstract":"<div><h3>Objective</h3><p>Dead-time loss is reported to be non-negligible for some patients with a high tumor burden in Lu-177 radionuclide therapy, even if the administered activity is 7.4 GBq. Hence, we proposed a simple method to shorten the apparent dead time and reduce dead-time loss using a thin lead sheet in previous work. The collimator surface of the gamma camera was covered with a lead sheet in our proposed method. While allowing the detection of 208-keV gamma photons of Lu-177 that penetrate the sheet, photons with energies lower than 208 keV, which cause dead-time loss, were shielded. In this study, we evaluated the usefulness of tungsten functional paper (TFP) for the proposed method using Monte Carlo simulation.</p><h3>Methods</h3><p>The count rates in imaging of Lu-177 administered to patients were simulated with the International Commission on Radiological Protection (ICRP) 110 phantom using the GATE Monte Carlo simulation toolkit. The simulated gamma cameras with a 0.5-mm lead sheet, 1.2-mm TFP, or no filter were positioned closely on the anterior and posterior sides of the phantom. The apparent dead times and dead-time losses at 24 h after administration were calculated for an energy window of 208 keV ± 10%. Moreover, the dead-time losses at 24–120 h were analytically assessed using activity excretion data of Lu-177-DOTATATE.</p><h3>Results</h3><p>The dead-time loss without a filter was 5% even 120 h after administration in patients with a high tumor burden and slow excretion, while those with a lead sheet and TFP were 0.22 and 0.58 times less than those with no filter, respectively. The count rates with the TFP were 1.3 times higher than those with the lead sheet, and the TFP could maintain primary count rates at 91–94% of those without a filter.</p><h3>Conclusions</h3><p>Although the apparent dead time and dead-time loss with the lead sheet were shorter and less than those with TFP, those with TFP were superior to those without a filter. The advantage of TFP over the lead sheet is that the decrease in primary count rates was less.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"199 - 207"},"PeriodicalIF":2.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-024-01987-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crossover evaluation of time-of-flight-based attenuation correction in brain 18F-FDG and 18F-flutemetamol PET","authors":"Takahiro Yamada,&nbsp;Kohei Hanaoka,&nbsp;Daisuke Morimoto-Ishikawa,&nbsp;Yoshiyuki Yamakawa,&nbsp;Shiho Kumakawa,&nbsp;Atsushi Ohtani,&nbsp;Tetsuro Mizuta,&nbsp;Hayato Kaida,&nbsp;Kazunari Ishii","doi":"10.1007/s12149-024-01986-6","DOIUrl":"10.1007/s12149-024-01986-6","url":null,"abstract":"<div><h3>Background</h3><p>Brain-dedicated positron emission tomography (PET) systems offer high spatial resolution and sensitivity for accurate clinical assessments. Attenuation correction (AC) is important in PET imaging, particularly in brain studies. This study assessed the reproducibility of attenuation maps (µ-maps) generated by a specialized time-of-flight (TOF) brain-dedicated PET system for imaging using different PET tracers.</p><h3>Methods</h3><p>Twelve subjects underwent both ¹⁸F-fluorodeoxyglucose (FDG)-PET and ¹⁸F-flutemetamol (FMM) amyloid-PET scans. Images were reconstructed with µ-maps obtained by a maximum likelihood-based AC method. Voxel-based and region-based analyses were used to compare µ-maps obtained with FDG-PET versus FMM-PET; FDG-PET images reconstructed using an FDG-PET µ-map (FDG × FDG) versus those reconstructed with an FMM-PET µ-map (FDG × FMM); and FMM-PET images reconstructed using an FDG-PET µ-map (FMM × FDG) versus those reconstructed with an FMM-PET µ-map (FMM × FMM).</p><h3>Results</h3><p>Small but significant differences in µ-maps were observed between tracers, primarily in bone regions. In the comparison between the µ-maps obtained with FDG-PET and FMM-PET, the µ-maps obtained with FDG-PET had higher µ-values than those obtained with FMM-PET in the parietal regions of the head and skull, in a portion of the cerebellar dentate nucleus and on the surface of the frontal lobe. The comparison between FDG and FDG × FMM values in different regions yielded findings similar to those of the µ-maps comparison. FDG × FMM values were significantly higher than FDG values in the bilateral temporal bones and a small part of the temporal lobe. Similarly, FMM values were significantly higher than FMM × FDG values in the bilateral temporal bones. FMM × FDG values were significantly higher than FMM values in a small area of the right cerebellar hemisphere. However, the relative errors in these µ-maps were within ± 4%, suggesting that they are clinically insignificant. In PET images reconstructed with the original and swapped µ-maps, the relative errors were within ± 7% and the quality was nearly equivalent.</p><h3>Conclusion</h3><p>These findings suggest the clinical reliability of the AC method without an external radiation source in TOF brain-dedicated PET systems.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"189 - 198"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET/CT biomarkers as predictors of long term outcomes and survival rates in patients with high risk malignant pulmonary masses/nodules treated with stereotactic ablative radiotherapy","authors":"Raef R. Boktor,&nbsp;Salvatore U. Berlangieri,&nbsp;Eddie Lau,&nbsp;Adeline Lim,&nbsp;Sylvia J. Gong,&nbsp;Xia Li,&nbsp;Andrew M. Scott","doi":"10.1007/s12149-024-01983-9","DOIUrl":"10.1007/s12149-024-01983-9","url":null,"abstract":"<div><h3>Introduction</h3><p>Stereotactic ablative body radiotherapy (SABR) is a standard treatment option for patients with malignant pulmonary masses (including primary and metastatic lesions) who are unfit for surgery or who are medically operable but refuse surgery. Flourine-18 flurodeoxyglucose positron emission tomography (¹⁸F-FDG PET) volumetric metabolic parameters, i.e., metabolic tumour volume (MTV) and total lesion glycolysis (TLG) play an important role in assessing the biological characteristics of some tumours and its role as potential prognostic factors has also been introduced.</p><h3>Objectives</h3><p>The aim of this retrospective study is to assess the value of baseline metabolic volumetric parameters as prognostic imaging biomarkers in patients with pulmonary masses/nodules treated with SABR.</p><h3>Methods</h3><p>70 patients were included in this retrospective study (39 male and 31 female, age range 47–91 years, mean 76 years). Standardized uptake value (SUVmax), SUVmean, MTV and TLG for all the patients were calculated on baseline ¹⁸F-FDG PET/CT. Patient outcome was divided into 3 categories free of disease, stable disease and disease progression.</p><h3>Results</h3><p>There was no significant statistical difference in the SUVmax and SUVmean in all the three categories. Mean SUVmax ranges from 7.13 to 8.08 with its highest value in the stable disease and lowest value in the progressive disease categories. Similarly, the average SUVmean was 4.9 in the free of disease category and 4.68 in the progressive disease category. MTV and TLG were low in the free of disease and the highest in progressive disease. MTV increased from 2.25 cm³ in free of disease category to 3.23 cm³ and 7.29 cm³ in stable disease and progressive disease, respectively. TLG has increased from 11.7 in the disease-free survival category to 18.77 and 40.39 in the stable and progressive disease, respectively. Patients with low MTV had longer overall survival (OS) than patients with high MTV (37 months versus 27 months, <i>p</i> value = 0. 0018). In addition, OS was longer in patients with low TLG (36 months versus 24 months, <i>p</i> value = 0.016).</p><h3>Conclusions</h3><p>TLG and MTV are more useful than SUVmax and SUVmean for predicting outcome, OS and progression-free survival (PFS) in patients receiving SABR. The TLG and MTV measurement on ¹⁸F-FDG PET imaging may be routinely recommended in baseline ¹⁸F-FDG PET/CT prior to SABR.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 2","pages":"158 - 166"},"PeriodicalIF":2.5,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advancements in new tracers from first-in-human studies","authors":"Yuji Nakamoto,&nbsp;Yoshitaka Inui,&nbsp;Masatoshi Hotta,&nbsp;Hiroshi Wakabayashi,&nbsp;Hirofumi Hanaoka","doi":"10.1007/s12149-024-01979-5","DOIUrl":"10.1007/s12149-024-01979-5","url":null,"abstract":"<div><p>Recent advancements in the development of positron emission tomography (PET) tracers have significantly enhanced our ability to image neuroinflammatory processes and neurotransmitter systems, which are vital for understanding and treating neurodegenerative and psychiatric disorders. Similarly, innovative tracers in oncology provide detailed images of the metabolic and molecular characteristics of tumors, which are crucial for tailoring targeted therapies and monitoring responses, including radiotherapy. Notable advancements include programmed death ligand 1 (PD-L1)-targeting agents for lung cancer, prostate-specific membrane antigen-based tracers for prostate cancer, chemokine receptor-targeting agents for hematological malignancies, human epidermal growth factor receptor 2 (HER2)-targeting tracers for various cancers, Claudin 18 based tracers for epithelial tumors, glutamine tracers for colorectal cancer, and ascorbic acid analogs for assessing cancer metabolism and therapy efficacy. Additionally, novel tracers have been developed for non-neurological and non-oncological applications, including adrenal imaging, amyloidosis, and human immunodeficiency virus (HIV) infection. This overview focuses on the newly developed tracers, particularly those used in neurology and oncology.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 11","pages":"877 - 883"},"PeriodicalIF":2.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-024-01979-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generative AI and large language models in nuclear medicine: current status and future prospects","authors":"Kenji Hirata,&nbsp;Yusuke Matsui,&nbsp;Akira Yamada,&nbsp;Tomoyuki Fujioka,&nbsp;Masahiro Yanagawa,&nbsp;Takeshi Nakaura,&nbsp;Rintaro Ito,&nbsp;Daiju Ueda,&nbsp;Shohei Fujita,&nbsp;Fuminari Tatsugami,&nbsp;Yasutaka Fushimi,&nbsp;Takahiro Tsuboyama,&nbsp;Koji Kamagata,&nbsp;Taiki Nozaki,&nbsp;Noriyuki Fujima,&nbsp;Mariko Kawamura,&nbsp;Shinji Naganawa","doi":"10.1007/s12149-024-01981-x","DOIUrl":"10.1007/s12149-024-01981-x","url":null,"abstract":"<div><p>This review explores the potential applications of Large Language Models (LLMs) in nuclear medicine, especially nuclear medicine examinations such as PET and SPECT, reviewing recent advancements in both fields. Despite the rapid adoption of LLMs in various medical specialties, their integration into nuclear medicine has not yet been sufficiently explored. We first discuss the latest developments in nuclear medicine, including new radiopharmaceuticals, imaging techniques, and clinical applications. We then analyze how LLMs are being utilized in radiology, particularly in report generation, image interpretation, and medical education. We highlight the potential of LLMs to enhance nuclear medicine practices, such as improving report structuring, assisting in diagnosis, and facilitating research. However, challenges remain, including the need for improved reliability, explainability, and bias reduction in LLMs. The review also addresses the ethical considerations and potential limitations of AI in healthcare. In conclusion, LLMs have significant potential to transform existing frameworks in nuclear medicine, making it a critical area for future research and development.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 11","pages":"853 - 864"},"PeriodicalIF":2.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}